In human cancers with deregulated Ras signalling, including tumours that have inactivated the Nf1 tumour suppressor, the cascade comprising Raf, mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) is a therapeutic target. Here, in mice, the effects of inhibitors of MEK in a model of myeloproliferative disorder initiated by inactivating Nf1 and in a model of acute myeloid leukaemia are compared.
- Jennifer O. Lauchle
- Doris Kim
- Kevin Shannon